Translocation of silver nanoparticles in the ex vivo human placenta perfusion model characterized by single particle ICP-MS by Vidmar, Janja et al.
 
 
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright 
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
 Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
 You may not further distribute the material or use it for any profit-making activity or commercial gain 
 You may freely distribute the URL identifying the publication in the public portal 
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
  
 
   
 
 
Downloaded from orbit.dtu.dk on: Oct 23, 2019
Translocation of silver nanoparticles in the ex vivo human placenta perfusion model
characterized by single particle ICP-MS
Vidmar, Janja; Löschner, Katrin; Correia, Manuel; Larsen, Erik Huusfeldt; Manser, Pius; Wichser, Adrian;
Boodhia, Kailen; S. Al-Ahmady, Zarhaa; Ruiz, Jaimé; Astruc, Didier
Published in:
Nanoscale
Link to article, DOI:
10.1039/C8NR02096E
Publication date:
2018
Document Version
Peer reviewed version
Link back to DTU Orbit
Citation (APA):
Vidmar, J., Löschner, K., Correia, M., Larsen, E. H., Manser, P., Wichser, A., ... Buerki-Thurnherr, T. (2018).
Translocation of silver nanoparticles in the ex vivo human placenta perfusion model characterized by single
particle ICP-MS. Nanoscale, 10, 11980-11991 . https://doi.org/10.1039/C8NR02096E
This is an Accepted Manuscript, which has been through the  
Royal Society of Chemistry peer review process and has been 
accepted for publication.
Accepted Manuscripts are published online shortly after 
acceptance, before technical editing, formatting and proof reading. 
Using this free service, authors can make their results available 
to the community, in citable form, before we publish the edited 
article. We will replace this Accepted Manuscript with the edited 
and formatted Advance Article as soon as it is available.
You can find more information about Accepted Manuscripts in the 
author guidelines.
Please note that technical editing may introduce minor changes 
to the text and/or graphics, which may alter content. The journal’s 
standard Terms & Conditions and the ethical guidelines, outlined 
in our author and reviewer resource centre, still apply. In no 
event shall the Royal Society of Chemistry be held responsible 
for any errors or omissions in this Accepted Manuscript or any 
consequences arising from the use of any information it contains. 
Accepted Manuscript
rsc.li/nanoscale
Nanoscale
www.rsc.org/nanoscale
ISSN 2040-3364
PAPER
Qian Wang et al.
TiC2: a new two-dimensional sheet beyond MXenes
Volume 8 Number 1 7 January 2016 Pages 1–660
Nanoscale
View Article Online
View Journal
This article can be cited before page numbers have been issued, to do this please use:  J. Vidmar, K.
Loeschner, M. Correia, E. H. Larsen, P. Manser, A. Wichser, K. Boodhia, Z. S. Al-Ahmady, J. Ruiz, D. Astruc
and T. Buerki-Thurnherr, Nanoscale, 2018, DOI: 10.1039/C8NR02096E.
Nanoscale  
PAPER 
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 1  
Please do not adjust margins 
Please do not adjust margins 
Received 00th January 20xx, 
Accepted 00th January 20xx 
DOI: 10.1039/x0xx00000x 
www.rsc.org/ 
Translocation of silver nanoparticles in the ex vivo human 
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With the extensive use of silver nanoparticles (AgNPs) in various consumer products their potential toxicity is of great 
concern especially for highly sensitive population groups such as the pregnant women and even the developing fetus. To 
understand if AgNPs are taken up and cross the human placenta, we studied their translocation and accumulation in the 
human ex vivo placenta perfusion model by single particle ICP-MS (spICP-MS). The impact of different surface 
modifications on placental transfer was assessed by AgNPs with two different modifications: polyethylene glycol (AgPEG 
NPs) and sodium carboxylate (AgCOONa NPs). AgNPs and ionic Ag were detected in the fetal circulation in low but not 
negligible amounts. Slightly higher Ag translocation across the placental barrier for perfusion with AgPEG NPs and higher 
AgNPs accumulation in placental tissue for perfusion with AgCOONa NPs were observed. Since these AgNPs are soluble in 
water, we tried to distinguish between the translocation of dissolved and particulate Ag. Perfusion with AgNO3 revealed 
the formation of Ag containing NPs in both circulations over time, of which the amount and their size in the fetal 
circulation was comparable to those from perfusion experiments with both AgNP types. Although we were not able to 
clarify whether intact AgNPs and/or Ag precipitates from dissolved Ag cross the placental barrier, our study highlights that 
uptake of Ag ions and/or dissolution of AgNPs in the tissue followed by re-precipitation in the fetal circulation needs to be 
considered as an important pathway in studies of AgNP translocation across biological barriers. 
Introduction 
Silver nanoparticles (AgNPs) are, due to their antibacterial 
properties, one of the most widely used engineered NPs, and 
are found in many commercial and medical products (e.g. food 
packaging, textiles, laundry detergents, prosthetic devices, 
dietary supplements, cosmetics). Humans may come into 
contact with AgNPs either accidentally (e.g. through exposure 
from contaminated drinking water, inhalation or by direct skin 
contact) or intentionally (e.g. in the case of nanomedical 
wound dressings or other applications).
1
 This raises concerns 
about AgNP accumulation, long-term retention in an organism 
and subsequent adverse health effects. There is increasing 
evidence for potential human toxicity of AgNPs
2
 and possible 
mechanisms of AgNP toxicity have been described and include 
their adverse effects on cell membranes, mitochondria and 
genetic material, causing induction of reactive oxygen species 
(ROS), oxidative stress, genotoxicity and apoptosis.
2–4
 
The growing fetus is particularly vulnerable to harmful 
compounds even at concentrations that are non-toxic for 
adults. Although the placenta provides a protective barrier for 
the entry of harmful substances, previous studies have 
demonstrated that some NPs can pass the placental barrier 
and induce pregnancy or fetal complications in pregnant 
rodents.
5–8
 For AgNPs, no developmental toxicity has been 
observed after repeated-dose oral administration in rats.
9–11
 In 
contrast, exposure to AgNPs induced teratogenic effects in 
mice
12–14
 and aquatic species.
15,16
 For instance, pulmonary 
exposure of pregnant mice to AgNPs induced an increased 
number of resorbed fetuses
14
 or long-lasting impairment of 
lung development of the offspring.
13
 However, results from 
animal experiments cannot directly be extrapolated to humans 
due to substantial differences in placental development, 
structure and function among species.
17,18
 The most promising 
and clinically relevant model for studying accumulation and 
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transport of substances across the human placenta is the ex 
vivo human placental perfusion system developed by Panigel 
et al.
19
 Although this model is increasingly being used to study 
the transfer of different NPs,
20,21
 no study with AgNPs has 
been performed so far. The only available data on potential 
transplacental transfer of AgNPs are from rodent studies, 
where increased Ag concentrations were detected in fetal 
organs.
11,13,22–24
 Recently, the visualization of AgNPs with 
similar sizes as those of the applied AgNPs in the placenta and 
fetal tissues has been interpreted as an indicator for placental 
transfer of these particles.
13
 However, it is not yet clearly 
established if Ag transfer occurs in particulate or ionic forms 
and how different AgNP properties and functionalizations 
affect placental barrier crossing. 
In general, NP toxicity, cellular uptake or transfer across 
biological barriers depend not only on particle concentration, 
but also on their physicochemical properties,
25
 surface 
modification, agglomeration
26
 and dissolution.
27
 Dissolution of 
AgNPs, also in complex biological systems, has been widely 
reported in the literature
28
 but there is a lack of consensus if 
AgNP-mediated toxicity is driven by the particles per se, the 
released Ag ions, or their combination.
29
 Some evidence that 
the release of Ag ions from NPs is responsible for their toxic 
effects toward organisms has been provided by several studies 
showing that AgNPs did not have bactericidal and cytotoxic 
effects when no dissolution of the NPs occurred
28,30
 or that 
dissolved Ag had similar neurotoxic effects as AgNPs.
31
 
A common problem for the reliable quantification and 
characterization of NPs under realistic exposure 
concentrations, where transfer rates are expected to be very 
low, is the insufficient limit of detection (LOD) of many 
analytical methods (both in terms of NP concentration and 
size) as well as problems related to matrix interferences and 
availability of efficient sample preparation methods.
8,32
 
Inductively coupled plasma-mass spectrometry in single 
particle mode (spICP-MS), established by Degueldre et al.,
33
 
has become a technique of choice for studying metal-
containing NPs in various matrices. spICP-MS is capable of 
providing information on the number-based particle size 
distribution and quantifying particle number and mass 
concentration as well as mass concentration of the dissolved 
fraction of the element in question. In spICP-MS analysis, a 
highly diluted suspension of NPs (particle mass concentrations 
usually in the range of ng/L) and use of short dwell times (from 
a few hundred microseconds to a few milliseconds) are 
required. Under ideal conditions, each recorded signal 
corresponds to a single particle. The frequency of ICP-MS 
signals can be used to determine the NP number 
concentration, while the intensity of the signals is related to 
the mass of the detected element in the NP and thus to its size 
under the assumption of a spherical particle 
34
. Furthermore, 
spICP-MS does not require demanding sample preparation for 
aqueous suspensions (only dilution), while for NPs in tissue 
samples, appropriate digestion procedures have to be 
applied.
35,36
 
The goal of this study was the investigation of AgNP 
translocation across the human placental barrier in 
dependence of negative or neutral surface modifications 
(COONa versus PEG). Since AgNPs can dissolve, one of the aims 
was to investigate if precipitation of AgNPs from Ag ions 
occurred. Perfusion experiments were performed using the ex 
vivo human placenta perfusion model, which for the first time 
enabled studying translocation and accumulation of AgNPs in a 
human model. 
Experimental section 
Nanoparticles  
AgNPs (AgPEG and AgCOONa NPs) were provided within the 
EU FP7 Nanosolutions project (www.nanosolutionsfp7.com). 
The AgNPs were custom-synthesized for the Nanosolutions 
project to mimic commercial NPs in order to provide a more 
realistic, real-life safety assessment. A detailed description of 
the AgNP synthesis and characterization is presented in 
Supplementary information. AgNPs were provided as aqueous 
suspensions with a particle mass concentration of 10 mg/mL in 
50 mL brown glass vials (as protection from ambient light).  
 
Ex vivo human placental perfusion and sample collection 
Placentas were obtained from uncomplicated term 
pregnancies after caesarean section at the Cantonal Hospital 
or Klinik Stephanshorn in St.Gallen. Written informed consent 
was obtained prior to delivery. The project was approved by 
the local ethics committee (EKSG 10/078) and performed in 
accordance with the principles of the Declaration of Helsinki. 
The placenta perfusion experiments were performed on a 
human ex vivo placenta perfusion model at the Swiss Federal 
Laboratories for Materials Science and Technology (Empa) as 
described previously.
37–39
 Criteria for a successful perfusions 
were leak from fetal to maternal circulation of < 4ml/h and 
stable pH (7.2-7.4). The perfusion medium (PM) was M199 
tissue culture medium (Sigma, St. Louis, MO, USA) diluted 1:2 
with Earl’s buffer and supplemented with 1 g/L glucose (Sigma, 
St. Louis, MO, USA), 10 g/L bovine serum albumin (AppliChem 
GmbH, Darmstadt, Germany), 10 g/L dextran 40 (Sigma, St. 
Louis, MO, USA), 2500 IU/L sodium heparin (B. Braun Medical 
AG, Melsungen, Germany), 250 mg/L amoxicillin 
(GlaxoSmithKline AG, Brentford, UK) and 2.2 g/L sodium 
bicarbonate (Merck, Darmstadt, Germany). Prior to the 
experiments, AgNPs stock suspensions were gently mixed by 
inverting the vial, diluted 250-times (AgPEG) or 135-times 
(AgCOONa) in PM and immediately used for placental 
perfusion studies. The resulting Ag mass concentrations for 
AgPEG and AgCOONa NPs in the maternal circulation at the 
start of the experiment were 12.48 µg/mL and 39.26 µg/mL, 
respectively, which corresponded to 40 µg/mL and 75 µg/mL 
of particle mass concentrations including coating, respectively. 
The experiments were performed in triplicates (N=3) for each 
AgNP type. Maternal and fetal perfusates were sampled in 
duplicate (experimental subsamples) after 0, 1, 3 and 6 h of 
perfusion. In order to assess possible precipitation of insoluble 
silver salts as particles, perfusion with 1 µg/mL of ionic Ag 
(AgNO3) (N=3) was performed. This concentration was selected 
as the maximum amount of ionic Ag present in the stock 
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solution of AgNPs. Control perfusion with PM without addition 
of AgNPs (N=1) was also conducted to examine the 
background levels of Ag.  
In order to investigate the degree of AgNPs accumulation, 
placental tissue samples from the villous chorion were 
collected before (0 h) and after each perfusion experiment 
(after 6 h) and homogenized by mixing 2 g of tissue in 2 mL of 
perfusion buffer (dilution factor of 2). All samples for spICP-MS 
analysis, i.e. perfusates and tissue homogenates, were 
immediately delivered to the Technical University of Denmark 
at 4°C and analyzed by spICP-MS within 3 days. A part of the 
replicates (N=1 for AgPEG NPs and N=2 for AgNO3) were 
performed one year later. 
 
DLS measurements 
Determination of hydrodynamic size and size distribution of 
AgNPs in UPW (resistivity 18.2 mΩ/cm), obtained from a 
Millipore Element apparatus (Millipore, Milford, MA, USA) and 
PM was performed by DLS (Zetasizer, Malvern Instruments, 
UK). The measurements were carried out using dust-free 
disposable cuvettes (DTS0012, Malvern Instruments, UK). The 
measurement position was fixed at the center of the cuvette 
(4.65 mm from the cuvette wall). The detection angle was 173° 
and the measurement was performed at a temperature of 25 
°C, which was achieved following equilibration for 1-2 minutes. 
Five consecutive measurements were performed using a 
minimum of 11 runs of 10 s each. The results obtained by DLS 
of the measured samples, given as Z-average (Zave) and 
polydispersity index, were determined by averaging the results 
of the five repeated measurements (N=5) for one diluted 
AgNPs suspension.  
 
Enzymatic tissue digestion 
For the enzymatic treatment of tissue, the enzyme solution 
was prepared by diluting 3 mg/mL of Proteinase K (commercial 
protease from Engyodontium album) and 0.5% (m/v) sodium 
dodecyl sulphate (SDS, ReagentPlus with ≥ 98.5% purity) in 
enzyme buffer, consisting of 50 mM ammonium bicarbonate 
buffer (with 99% purity) and 200 µg/mL sodium azide (with ≥ 
98% purity), all purchased from Sigma-Aldrich (St. Louis, MO, 
USA) at pH 7.4 (PHM 240 pH/ION meter from Radiometer, 
Copenhagen, Denmark). To allow double determinations, each 
homogenated sample was divided into two subsamples before 
enzymatic treatment. A mass of 0.2 g of tissue homogenate 
(corresponding to 0.1 g of wet tissue) was weighed into plastic 
tubes with round bottom (Karter Scientific Labware 
Manufacturing, Lake Charles, LA, USA). After the addition of 
2.0 mL of the enzyme solution (60 µg of enzyme per mg of wet 
tissue) and 300 µL of UPW, samples were shortly vortexed 
with a MS2 minishaker (IKA Works, Inc., Wilmington, NC, USA) 
until no sample adhered to the tube walls. The samples were 
placed in the water bath at 37°C (HetoHMT 200 RS thermostat) 
and magnetically stirred with the use of Telesystem HP15 
magnetic stirrer (Holm & Halby, Allerød, Denmark) for 1 h. At 
the end of enzymatic treatment, the completely digested 
samples were placed in ice water to slow down the enzymatic 
digestion process and appropriately diluted with UPW prior to 
spICP-MS measurements.  
 
spICP-MS analysis 
A Thermo Scientific iCAP Q ICP-MS instrument (Thermo Fisher 
Scientific GmbH, Bremen, Germany) was used for single 
particle measurement of the samples from all the perfusion 
experiments with the following practical exceptions. For the 
samples from one of the perfusion experiments with AgCOONa 
NPs an Agilent 8800 Triple Quadrupole ICP-MS instrument 
(Agilent Technologies, California, USA) was applied and an 
Agilent 7900 ICP-MS instrument was used for measuring the 
samples from one perfusion experiment with AgPEG NPs and 
two perfusion experiments with AgNO3. Instrument tuning was 
performed prior to analysis by using a tuning solution 
according to the manufacturer’s recommendation. Settings for 
all three instruments are given in Table S1. 
Accurate sample flow rate was determined daily by 
weighing. Quantification of particle size (particle diameter) 
was based on a calibration curve constructed from a blank 
(UPW) and four concentration levels of certified standard 
solutions of Ag (1000 µg/mL, PlasmaCAL, SCP Science, Baie 
D'Urfé, QC, Canada) ranging from 0.2 to 2.0 ng/mL. For each 
sample, the isotope 
107
Ag was detected using 3 ms dwell time 
for a total measurement time of 180-600 s (equivalent to 
60,000-200,000 data points).  
The recorded signal intensity data were plotted (in cps) 
versus number of “events”, to create a signal distribution 
histogram using Microsoft Excel (Microsoft, WA, USA). The 
threshold between signals from instrumental noise/dissolved 
Ag and particulate Ag was set to a value that gives a lowest 
detectable particle diameter of 25 nm. This value 
corresponded to the maximum of dissolved Ag concentration 
that was found in the PM samples from the maternal side at 
time 0h (i.e., up to 68 ng/L in diluted samples). Lower 
diameters (down to 13 nm) could be detected in fetal 
perfusates and maternal perfusates collected at longer 
perfusion times. However, the application of the same 
threshold for all samples ensured that a direct comparison of 
particle mass and number concentrations as well as median 
particle diameters between samples was possible. The Ag mass 
fraction below the selected threshold was used to estimate 
the mass concentration of dissolved Ag and AgNPs smaller 
than 25 nm.  
The transport efficiency of the liquid NP samples through 
the sample introduction system was determined according to 
the “particle size” method
40
 with the use of reference gold 
nanoparticle suspension (RM8012), obtained from the 
National Institute for Science and Technology (NIST, 
Gaithersburg, MD, USA) with a known average particle 
diameter (27.6 ± 2.1 nm as determined by TEM) and gold mass 
concentration (48.17 ± 0.33 µg/g). This suspension, diluted 
10
7
-times with UPW, in combination with a calibration curve 
made of dissolved Au standards (0, 0.5 and 1 ng/mL) (1000 
µg/mL Au standard, PlasmaCAL from SCP Science, Baie D'Urfé, 
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QC, Canada) was used to determine the transport efficiency of 
the NPs. With the use of AuNPs, a calibration curve that relates 
the most common signal intensity to the average particle mass 
was created. Then, a corresponding calibration curve from the 
dissolved Au standards was constructed by multiplying 
dissolved Au standard concentration by the sample flow rate 
and the dwell time to calculate the total Au mass. Finally, the 
ratio of the slope from the calibration curve made from the 
ionic Au standards and the slope from the calibration curve 
created from the AuNPs was used to determine the transport 
efficiency. To assess the accuracy of the transport efficiency 
determined by the “particle size“ method with the use of 
AuNPs, the “particle frequency“ method
40
 using 40 nm AgPEG 
NPs (NanoXact Silver Nanospheres, purchased from 
Nanocomposix, San Diego, CA, USA) was applied. There was no 
significant difference in the so determined transport 
efficiencies. For the validation of the spICP-MS method, the 
particle number concentration of 40 nm AgPEG NPs 
(Nanocomposix) was determined and compared to the 
expected particle number concentration (calculated from the 
size provided by TEM and Ag mass concentration provided by 
ICP-MS), where 95 ± 1 % (N=2) recovery was achieved. 
Complete ionization of AgNPs was confirmed by the 
comparable Ag concentrations observed for the digested (i.e., 
dissolved) AgCOONa NPs (determined by conventional ICP-MS) 
and undigested AgCOONa NPs (determined by spICP-MS) (Fig. 
S1). 
To prevent AgNPs from sticking to the ICP-MS tubings and 
to avoid a memory effect during ICP-MS measurements, the 
following washing procedure was applied after each sample: 1) 
1% (v/v) HCl (34-37%), 1% (v/v) HNO3 (67-69%), both of 
PlasmaPURE quality, and 0.1% (m/v) Triton X-100 (Merck, 
Darmstadt, Germany) for 1 min at 1.5 mL/min, 2) UPW for 30 s 
at 1 mL/min. Following the analysis of each sample, UPW was 
aspirated into the ICP-MS for additional rinsing and to ensure 
that no carryover from the previous measurement was 
detectable. 
Prior to spICP-MS analysis, two (analytical) subsamples 
were taken from each experimental subsample of perfusate 
and diluted with ultrapure water (UPW). The list of analyzed 
samples together with suitable dilution factors and total 
measurement times, which were determined experimentally, 
are presented in Table S2. For the sake of counting statistics, a 
minimum number of 400 particles were detected per sample 
and the ratio between detected particles and number of 
dwells restricted to a maximum of 20% to limit the probability 
of multiple particle events during one dwell to 10%. The 
results for the translocation experiments are expressed as Ag 
mass concentration in perfusates normalized to the Ag mass 
concentration measured on the maternal side at time 0 h 
(M0). Ag mass concentrations determined in placental tissues, 
collected before the start of perfusion, were subtracted from 
the Ag values determined in tissues after 6h of perfusion. 
Results were expressed as Ag mass concentrations in the 
tissues that were normalized to the applied Ag dose, measured 
in M0 samples by conventional ICP-MS, taking into account the 
total mass of the placenta tissue and the total volume of 
perfusate. Since there was not enough MO sample (maternal 
perfusate after 0 min of perfusion) left from one of the 
perfusion with AgCOONa NPs for conventional ICP-MS analysis, 
M15 sample, collected shortly after the beginning of perfusion 
(15 min), was used to estimate the starting concentration. This  
Table 1 Summary of AgNP stock suspension characteristics 
AgNP characteristic AgPEG AgCOONa 
Ag mass concentration (mg/mL) 3.12 ± 0.06 5.30 ± 0.01 
Mass fraction of dissolved Ag (w/w 
%) 
4.9 ± 0.1 0.11 ± 0.01 
Mass fraction of surface 
modification (w/w %) 
64.1 16.3 
Primary particle diameter (nm) 2-15  5-15  
Zeta potential at pH 5 in UPW (mV) -10.7 ± 0.4 -32.5 ± 1.1 
Results for Ag mass concentration (N=3), mass fraction of dissolved Ag (N=2) and 
zeta potential (N=5) are presented as mean ± STD 
might lead to a slight underestimation of the tissue 
concentration, however, the error is likely smaller than the 
biological variations observed between the individual 
experiments. 
 
Behavior of AgNPs in perfusion medium 
For studying aggregation of AgNPs in PM by DLS and spICP-MS, 
AgPEG and AgCOONa NPs stock suspensions were diluted in 
UPW or PM 5- and 10-times, respectively, (in case of DLS 
analysis) and 125- and 1000-times, respectively (in case of 
spICP-MS analysis). In order to assess if Ag ions could  
precipitate as NPs in PM, different concentrations of ionic Ag 
(100 µg/mL, 10 µg/mL and 1 µg/mL) were prepared in PM and 
their size distributions measured by DLS immediately after 
their preparation and 4 days later after storage at room 
temperature (RT). spICP-MS was applied for detecting possible 
formation of Ag precipitates in PM in the lower concentration 
range (4, 2 and 0.2 µg/mL), over a period of 3 days at RT. Prior 
to spICP-MS analysis (3 min measurement time), samples 
containing 4, 2 and 0.2 µg/mL ionic Ag were diluted 4,000, 
2,000 and 200-times, respectively. PM was diluted in the same 
way and measured after each sample. 
 
Statistical analysis 
Results based on repeated measurements are given as mean ± 
one standard deviation (STD). The number of repetitions N is 
stated in parentheses. Data (comparison of quantiles of 
particle size distributions at different perfusion times, 
repeatability and reproducibility for sizing and quantification 
of AgNPs) were statistically analyzed by using one-way Analysis 
of Variance (ANOVA) in Microsoft Office Excel 2010 (Microsoft, 
Redmond, WA, USA). A p-value ≤ 0.01 was considered 
statistically significant. 
Results and discussion 
Characterization of AgNPs  
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The basic characteristics for the stock suspensions of both 
AgNP types, including total Ag mass concentration, mass 
fraction of dissolved Ag, mass fraction of surface modification, 
primary particle size and zeta potential are presented in Table 
1. Besides revealing primary particle size, TEM analysis further 
showed that AgPEG suspension contained three populations ¨-
Ag spheres of 2-8 nm, Ag spheres close to 7-15 nm, and a third 
minor population of large and irregular particles in the 200-
1000 nm size range. The AgCOONa NP suspensions comprised, 
besides the primary particles, large assemblies of 100-500 nm 
containing multiple individual Ag spheres of 5-15 nm (Fig. S2).
Table 2 Mass concentrations and median diameters of AgNPs, dispersed in UPW and PM, determined by spICP-MS. Results 
present mean values ± STD from two replicates 
*Based on ICP-MS analysis of digested stock suspensions 
**Based on the total Ag mass concentration determined by spICP-MS (≤ 25 nm + > 25nm) 
*** Ag mass concentration (≤ 25 nm + >25 nm) determined by spICP-MS in comparison to the Ag mass concentration determined by conventional ICP-MS after acid 
digestion  
All NPs have been tested for endotoxin contamination and 
were endotoxin free (<0.5 EU/mL in Chromogenic LAL assay). 
Stability of AgNPs in perfusion medium  
In order to assess if AgNPs aggregated/agglomerated in PM, 
hydrodynamic size and size distribution of AgNPs in UPW and 
PM were determined by DLS (Fig. 1). Size distributions 
obtained for AgPEG and AgCOONa NPs in UPW were in 
agreement with the TEM results (Fig. S2). For AgPEG NPs in 
PM, a slightly broader size distribution was observed in 
comparison to UPW. Size distribution for pure PM (peaks 
around 10 nm and 500 nm – data not shown) indicated that 
the size distributions of AgNPs in PM can be attributed to the 
AgNPs and not to scattering entities in the PM. For AgCOOH 
NPs in PM, the size distribution shifted to significantly larger 
sizes with the peak maximum at 1000 nm due to 
agglomeration/aggregation of the NPs.  
Agglomeration/aggregation of AgCOONa NPs in PM was 
further confirmed by spICP-MS measurements (Table 2 and 
Fig. 2). While size distributions and mass concentrations of 
AgPEG NPs were similar in UPW and PM, AgCOONa NPs 
aggregated/agglomerated in PM resulting in bigger median 
diameters, higher mass concentration of AgNPs > 25 nm and 
lower mass concentration of AgNPs ≤ 25 nm in comparison to 
UPW.  
 
Translocation of Ag across the human placental barrier 
AgNP type Medium 
Expected Ag 
mass conc.* 
(µg/mL) 
Mass conc. of 
AgNPs > 25 nm  
(µg/mL) 
Mass conc. of AgNPs ≤ 
25 nm + Ag ions  
(µg/mL) 
Mass fraction of 
AgNPs > 25 nm** 
(%) 
Ag mass 
recovery 
*** (%) 
Median 
particle 
diameter (nm) 
AgPEG 
 
UPW 
12.5 
0.141 ± 0.004 9.05 ± 0.24 1.5 73.6 27.7 ± 0.3 
PM 0.121 ± 0.004 8.98 ± 0.14 1.3 72.9 27.4 ± 0.3 
AgCOONa 
 
UPW 
39.3 
13.5 ± 0.3 17.0 ± 0.7 44 77.6 34.3 ± 0.3 
PM 29.1 ± 2.0 7.65 ± 0.31 79 93.6 40.8 ± 0.4 
Fig. 2 Size distributions of AgPEG NPs and AgCOONa NPs, dispersed in ultrapure water 
or perfusion medium. The minimum detectable size by spICP-MS was 25 nm. In case of 
AgCOONa NPs in perfusion medium, NPs up to 270 nm nm were detected. Size 
distributions are representative of two replicates for each medium and each AgNP 
type. 
Fig. 1 DLS hydrodynamic size measurements of AgNPs dispersed in ultrapure water or 
perfusion medium. Intensity-based size distributions of AgPEG (left) and AgCOONa NPs 
(right), dispersed in ultrapure water (UPW) or perfusion medium (PM) at Ag mass 
concentration of approximately 0.3 mg/mL. The data is representative of five (N=5) 
consecutive DLS measurements for each AgNPs type and media. 
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40 µg/ml AgPEG NPs (12.5 µg/ml Ag) or 74 µg/ml AgCOONa 
(39 µg/ml Ag) were added to the maternal circulation in an ex 
vivo placenta perfusion model, and changes of Ag mass 
concentrations of the fraction > 25 nm and the fraction ≤ 25 
nm (AgNPs ≤ 25 nm and dissolved Ag) were followed over the 
time of perfusion in maternal and fetal circulations by spICP-
MS (Fig. 3). AgPEG NPs and AgCOONa NPs were selected as 
AgNPs with neutral and negatively charged surface 
modifications, respectively, since studies showed that cellular 
uptake and translocation of negatively charged NPs is less 
likely to occur compared to neutral or positively charged 
NPs.
20,41–43
 The concentrations of AgNPs were chosen as doses 
that were non-toxic to BeWo trophoblast cells after 6 h of 
exposure according to an MTS viability assay (Fig. S8) but still 
relatively high to be able to detect particle uptake and/or 
translocation and to mimic a potential worst-case exposure 
scenario. 
After perfusion with AgCOONa or AgPEG NPs, Ag mass 
fraction > and ≤ 25 nm in the fetal circulation increased with 
time of perfusion but overall, only very low amounts of the 
maternally applied Ag doses were detected on the fetal side 
(Fig. 3). The mass percentage of Ag fraction > 25 nm that 
crossed the placental barrier after 6 h of perfusion was 0.0148 
± 0.0192% for AgPEG NPs (N=3) and 0.0002 ± 0.0002% for 
AgCOONa NPs (N=3). However, the highest placental 
translocation was not observed for the AgNPs > 25 nm but for 
the small AgNPs and/or Ag ions (fraction ≤ 25 nm) with 0.1578 
± 0.1032% for AgPEG NPs and 0.0151 ± 0.0077% for AgCOONa 
NPs. On the maternal side, the Ag fraction > 25 nm remained 
constant, while the Ag fraction ≤ 25nm decreased by 44% 
during 6 h of perfusion in case of AgPEG NPs. In the case of 
AgCOONa NPs, a strong decrease of both fractions was 
observed on the maternal side during the 6 h of perfusion 
(63% decrease for Ag fraction > 25nm and 13% decrease for Ag 
fraction ≤ 25nm).  
In addition to quantifying the Ag mass concentrations of 
different size fractions, spICP-MS analysis was also applied to 
obtain information about the (number-based) particle size 
distribution on the maternal side over increasing time of 
perfusion and on the fetal side at the end of perfusion (Fig. 4). 
For quantitative comparison of the particle size distribution 
the 2.5, 50 and 97.5% percentiles of the size distributions were 
calculated.  
For perfusion experiments with AgCOONa NPs, smaller 
particles were present in the fetal circulation at the end of 
perfusion (median particle diameter (MPD) 27.4 ± 0.6 nm) as 
compared to the maternal side at the beginning of perfusion 
(MPD 32.8 ± 0.5 nm). In contrast, there was no significant 
difference in the particle size distribution of AgPEG NPs 
between maternal (MPD 27.5 ± 0.3 nm) and fetal side (MPD 
28.7 ± 1.1 nm). In case of AgPEG NPs, a statistically significant 
shift (p < 0.01) for all three percentile values of particle size 
distribution towards larger particles occurred with time on the 
maternal side (MPD 29.0 ± 0.1 nm after 6h of perfusion) and 
reached a size similar to the one observed on the fetal side at 
the end of the perfusion. For AgCOONa NPs a statistically 
significant decrease of the particle size with perfusion time 
was observed (significant only for 50% percentile value) to a 
size of 30.8 ± 0.1 nm (MPD) on the maternal side after 6 h of 
perfusion.  
Fig. 3 Perfusion profiles of AgPEG and AgCOONa NPs during ex vivo human placental 
perfusion. Ag mass fraction >25nm (continuous line) and ≤ 25 nm (dashed line) were 
measured on the maternal (black color) and fetal side (gray color) over a time period of 
6 h by spICP-MS. Missing points present non-detectable concentrations (< LOD). Data 
represent the mean ± STD of the independent experiments (N=3 for AgPEG NPs, N=3 
for AgCOONa NP). 
Fig. 4 Size distributions of AgNPs formed in perfusion with AgPEG and AgCOONa NPs 
over time and determined by spICP-MS. Missing points present non-detectable 
concentrations (< LOD). Data represent the mean ± STD of the independent 
experiments (N=3 for AgPEG NPs, N=3 for AgCOONa NP). 
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To confirm the results obtained by spICP-MS total Ag mass 
concentrations on the maternal and fetal side for varying time 
of perfusion were also determined by conventional ICP-MS 
analysis and compared to the results obtained by spICP-MS (Ag 
mass fraction > + ≤ 25 nm, the latter includes also the 
dissolved Ag fraction) (Fig. S1). There was no significant 
difference (t-test, p < 0.01) between the Ag concentrations 
determined by both methods for the perfusion studies with 
AgCOONa NPs. However, in case of AgPEG NPs, about 3-times 
higher Ag concentrations were detected in the maternal 
perfusates at time 0h by ICP-MS compared to spICP-MS. This 
indicates unforeseen Ag mass losses during the spICP-MS 
measurements. We suspect that the surface properties (PEG 
coating) led to partial adhesion to the tubings of the sample 
introduction system of the ICP-MS. However, the recoveries 
were more favorable (73%) for AgPEG NPs freshly spiked to 
PM (Table 2). Nevertheless, reduced spICP-MS recoveries of 
AgPEG NPs do not have an impact on the obtained results, as 
relative changes were investigated. The percentage of total Ag 
that crossed the placental barrier (measured on the fetal side 
after 6 h of perfusion) was 0.0239 ± 0.0197% for AgCOONa and 
0.0620 ± 0.0454% for AgPEG NPs when determined by 
conventional ICP-MS and 0.0152 ± 0.0080% for AgCOONa and 
0.0615 ± 0.0482% for AgPEG NPs when determined by spICP-
MS.  
 
Accumulation of Ag in the placental tissue 
Although placental Ag transfer was very low, Ag mass 
concentration in the maternal circulation was declining, in 
particular for AgCOONa NPs (Fig. 3). In order to investigate the 
degree of Ag accumulation in the placenta, tissue samples 
were enzymatically treated to release AgNPs and dissolved Ag 
from the tissue. Ag mass fraction > and ≤ 25 nm were 
measured in placental tissues after 6 h of perfusion with 
AgPEG NPs and AgCOONa NPs (Fig. 5).  
For AgCOONa NPs, a much higher Ag fraction > 25 nm of 
the applied dose accumulate in the placenta (4.2%) as 
compared to AgPEG NPs (0.75%), while the mass 
concentration of the Ag fraction ≤ 25 nm was 7.5% for 
AgCOONa NP and 15% for AgPEG. Overall, Ag mass fraction ≤ 
25 nm represented 95% and 64% of the total internalized Ag 
mass concentration (≤ 25 nm + > 25nm) for AgPEG and 
AgCOONa NPs, respectively. The amount of Ag determined in 
the placental tissue was therefore much higher in comparison 
to the translocated Ag (below 0.02% of Ag NPs > 25 nm for 
both AgNP types), suggesting that the transfer of Ag to the 
fetal circulation was substantially hindered by the placental 
barrier. Strong accumulation of Ag fraction > 25 nm in the 
placental tissue after the perfusion with AgCOONa NPs was 
reflected also through the decrease of the Ag concentration on 
the maternal side over time (Fig. 3). A possible explanation for 
the high Ag concentrations in placenta may be the presence of 
high levels of the metal-binding protein metallothionein in this 
tissue.
44
 The strong accumulation of Ag in the placental tissue 
is of potential threat to the developing fetus if it interferes 
with proper placental development and function or the release 
of mediators (e.g. inflammatory, angiogenic or endocrine 
factors) from placental tissue. Such indirect toxicity has been 
previously described in rodent and human in vitro placental 
transfer studies for CoCr NPs.
25,45,46
 Although we did not 
directly investigate the impact of Ag on placental tissue 
viability and functionality, the maintenance of barrier integrity 
throughout the perfusion experiments suggests the absence of 
major acute toxicity to the placenta. However, further studies 
would be required to understand the long-term consequences 
of high Ag tissue levels on placental function. In addition, even 
if placental transfer of Ag is low, direct teratogenic effects may 
occur from translocated Ag in particular for a chronic exposure 
scenario since the fetus is particularly vulnerable to toxic 
compounds already at low levels. Previous studies with 
pregnant rodents revealed that AgNPs may cause adverse 
Fig. 5 Ag mass concentrations in placental tissues from perfusion experiment with 
AgPEG and AgCOONa NPs. Ag mass fraction > and ≤ 25 nm were determined by spICP-
MS in enzymatically treated tissue samples. Ag mass concentrations in placenta 
collected after 6h of perfusion are normalized to the applied Ag concentration 
measured in M0 samples (initial concentrations in maternal perfusates) by 
conventional ICP-MS. Data represent the mean ± STD of the independent experiments 
(N=3 for AgPEG NPs, N=3 for AgCOONa NPs). 
Fig. 6 Size distributions of AgPEG and AgCOONa NPs on maternal, fetal side and in 
placental tissue. Size distributions were determined by spICP-MS after 6 h of 
perfusion and are representative of three independent perfusion experiments (N=3 
for AgPEG NPs, AgCOONa NPs and AgNO3).
Page 7 of 13 Nanoscale
N
an
os
ca
le
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
11
 Ju
ne
 2
01
8.
 D
ow
nl
oa
de
d 
by
 D
TU
 L
ib
ra
ry
 o
n 
11
/0
6/
20
18
 1
1:
29
:2
7.
 
View Article Online
DOI: 10.1039/C8NR02096E
ARTICLE Journal Name 
8 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx 
Please do not adjust margins 
Please do not adjust margins 
effects on embryo’s health.
13,47
 Moreover, there is recent 
evidence that AgNPs cause developmental neurotoxicity in 
human embryonic neural precursor/stem cells in vitro.
48,49
  
When comparing the sizes of AgNPs determined on the 
maternal and fetal side after 6h of perfusion with AgCOONa 
NPs with those in placental tissue (Fig. 6), we observed larger 
Ag particles (aggregates/agglomerates) on the maternal side 
and in the placental tissue compared to the smaller particles 
on the fetal side. In case of AgPEG NPs, there was no 
difference in MPDs on the maternal side, in placental tissue 
and on the fetal side.  
The presence and localization of AgNPs in placental tissue 
after 6 h of perfusion with AgPEG and AgCOONa NPs was also 
assessed by CytoViva dark field microscopy (Fig. S4). The 
technique has the ability to detect a broad range of differently 
sized NPs (from small monodispersed NPs50 up to large NP or 
NP agglomerates/aggregates51) and to distinguish between NP 
types if spectral profiles are sufficiently distinct.50 Particulates 
were observed in all perfused tissues and were mainly 
localized in the syncytiotrophoblast layer. Particulates were 
neither detected in control samples of placental tissue 
perfused with perfusion medium only nor in placental tissue 
sections taken before perfusion with AgNPs. To further verify 
the specificity of the Ag signals, scans were also performed on 
AgNP suspensions alone to generate spectral libraries, which 
were then mapped onto the scans of the NP-perfused tissues 
using the image classification algorithm, spectral angle mapper 
(Fig. S5 and S6). Positive signals of particulate Ag were 
identified but an unambiguous identification of all AgNP 
signals was not possible since the spectral profile of the 
particles changed in the tissue as compared to the spectral 
library of the NPs in stock solution. 
 
Translocation of dissolved Ag and formation of Ag containing 
particles 
Since AgNPs are soluble, one objective of the study was to 
distinguish between the translocation and uptake of dissolved 
and particulate Ag in the ex vivo placenta perfusion model. In 
our experiments with AgNPs, dissolved Ag was present on the 
maternal or fetal side either due to particle dissolution in PM 
during the perfusion experiment or due to the dissolved Ag 
fraction that was already present in the AgNP suspensions 
(4.9% for AgPEG and 0.11% for AgCOONa NP suspensions – 
Table 1) or both. Loza et al.28 have shown that the 
predominant species formed from dissolved Ag in biological 
media in the presence of chloride ions is colloidally dispersed 
nanoparticulate AgCl, whereas in tissues ionic Ag typically 
deposits as selenium and/or sulfur containing particles.52 We 
therefore assumed that AgCl precipitation from dissolved Ag 
would occur in the used PM. In order to study potential de 
novo formation of Ag containing NPs from ionic Ag during the 
perfusion experiment, DLS and spICP-MS analyses for different 
concentrations of ionic Ag in PM were performed. AgNP 
precipitation in PM (additional peak in the size distribution 
with a peak maximum at around 100-200 nm) was only 
detectable by DLS when the ionic Ag concentration was 10 
µg/mL or higher (Fig. S7). Even after prolonged incubation (4 
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days at RT), no Ag particle formation was evident at relevant 
concentrations of dissolved Ag (1 µg/mL) (data not shown), 
most probably because DLS is not sensitive enough to detect 
NP formation at such small concentrations. No Ag-containing 
NPs could be detected even by the more sensitive spICP-MS 
method in PM spiked with 2 or 4 µg/mL ionic Ag (2000- and 
4000-times diluted prior to analysis, respectively) (data not 
shown). In PM spiked with 0.2 µg/mL a very low number of 
NPs (92) was detected. A similar number (108) was, however, 
observed in the corresponding blank sample (200-times 
diluted PM) indicating that less diluted PM has a stronger 
ability to wash out AgNPs, adhered to ICP-MS tubes from 
previous measurements. Therefore, the particles detected in a 
freshly prepared 0.2 µg/mL ionic Ag sample solution are most 
probably the consequence of the particles wash-out rather 
than formation of AgNPs in PM. No Ag-containing NPs could be 
detected after 3 days incubation at RT either (data not shown). 
In summary, at experimentally ionic Ag concentrations of 0.2 
to 4 µg/mL no formation of Ag-containing NPs was observed. 
The minimum detectable particle size in all experiments with 
dissolved Ag was higher than in ex vivo perfusion experiments 
(approximately 47 nm) due to the lower degree of dilution of 
samples prior to spICP-MS analysis. A possible formation of 
particles smaller than this size cannot be excluded. By 
performing a perfusion experiment with dissolved Ag, we 
wanted to assess if the dissolved Ag was able to cross the 
placental barrier and if any Ag-containing NPs could form from 
the dissolved Ag in the presence of PM and placental 
tissue.
28,53,54
 After perfusion with 1 µg/mL AgNO3 (Fig. 7A), an 
increase of the Ag mass fraction ≤ 25 nm was measured in the 
fetal circulation over time by spICP-MS. Interestingly, Ag 
particles > 25 nm appeared in the maternal circulation (already 
at time 0 h) and their concentration increased gradually 
throughout the course of a perfusion experiment. A significant 
number of particles was formed on the maternal ((2.89 ± 1.23) 
x 10
7 
particles/mL) and fetal side ((1.10 ± 0.37) x 10
5
 
particles/mL) after 6 h of perfusion (N=3). The mass 
concentration of AgNP > 25 nm on the fetal side was 0.0165 ± 
0.0070 µg/L after 6 h of perfusion (Fig. 7A). This value was in 
the same concentration range as the mass concentration of 
AgNPs > 25 nm that was observed on the fetal side after 
perfusion with AgNPs (0.819 ± 1.074 µg/L for AgPEG (N=3) and 
0.081 ± 0.071 µg/L for AgCOONa (N=3)) (Fig. 3). The size 
distribution of the newly precipitated particles on the fetal 
side after 6 h (MPD 26.1 ± 0.4 nm) was similar to the size 
distribution of particles detected on the fetal side after AgPEG 
(MPD 28.7 ± 1.1 nm) or AgCOONa NPs (MPD 27.4 ± 0.6 nm) 
were added (Fig. S3 A). Moreover, the particle size on the 
maternal side increased with time of perfusion and larger 
particles were observed on the maternal side (MPD 31.9 ± 1.5 
nm) compared to the fetal side (MPD 26.1 ± 0.4 nm) after 6h 
of perfusion (Fig. 7B, Fig. S3 B). Finally, spICP-MS analysis 
revealed that predominantly Ag ions and/or small AgNPs were 
taken up by the placental tissue (18% for fraction ≤ 25 nm, 
0.02% for AgNPs > 25 nm) (Fig. 7C) and particulates similar to 
the ones observed after perfusion with AgNPs (Fig. S4) were 
observed in placental tissue sections by CytoViva dark field 
microscopy (Fig. 7D). 
The concentrations and size distributions of the particles 
detected on the fetal side after the addition of dissolved Ag 
were comparable to those from the AgNP perfusion 
experiments. The exact composition of the formed NPs could 
not be determined with spICP-MS, because only one element 
per particle could be detected. Since no particle formation was 
observed in PM, which contained relevant ionic Ag 
concentrations, the formation of NPs cannot be explained with 
interaction of Ag ions and PM only, but occurred most 
probably due to the presence of proteins in the placental 
tissue. For instance, amino acids containing thiol groups (i.e. 
cysteine) have a high affinity for ionic Ag, forming Ag(I)–sulfide 
complexes.
55
 Bolea et al.
56
 substantiated this by showing that 
association of dissolved Ag released from AgNPs with the 
proteins is accelerated in the presence of cells. 
Consequently, the observed presence of NPs in the fetal 
circulation in ex vivo perfusion experiments with AgNPs could 
therefore be either the result of the translocation of the 
pristine AgNPs (scenario 1) or be caused by the translocation 
and subsequent reduction or reaction with available ligands of 
dissolved Ag (originating from AgNPs dissolution) (scenario 2). 
With the use of the spICP-MS method that provides 
information only about particle size and not about the 
complete particle composition we were not able to 
unambiguously confirm the exact mechanism. Assuming the 
first scenario, quantitatively different degrees of Ag 
translocation of AgPEG NPs and AgCOONa NPs across the 
placenta could be explained by their different size distributions 
in PM as a result of different surface modifications: AgCOONa 
NPs formed large agglomerates/aggregates in the micrometer 
size range in PM. In contrast, the size distribution of AgPEG 
NPs was not significantly changed in PM (Table 2, Fig. 1). The 
higher degree of agglomeration/aggregation observed for 
AgCOONa NPs in PM could be attributed to the carboxylate 
groups which become less ionized at high ionic strength in PM. 
The repulsive forces between AgCOONa NPs are thereby 
weakened, leading to particle aggregation. PEG coating, on the 
other hand, provides strong steric stabilization for the AgPEG 
NPs even in solution with high ionic strength. Since 
agglomeration of NPs is expected to significantly reduce 
placental transfer,
20,37
 a higher dose of AgCOONa NPs 
compared to AgPEG NPs was applied to the maternal 
circulation. However, even at higher initial concentrations in 
the PM, the percentage of AgNPs in fetal perfusates was lower 
for AgCOONa than for AgPEG NPs. To conclude, the influence 
of NP surface charge/modification on translocation could not 
be studied as a single factor as it also affected the 
agglomeration of NPs in perfusion medium and consequently 
the size distribution. 
NP size has been shown to be a key determinant in 
placental transfer with lower transfer for larger NPs.
20
 Further 
evidence that size is the key determinant for AgNP 
translocation was reflected in a more efficient translocation of 
small AgNPs/ionic silver (Ag fraction ≤ 25 nm) across the 
placental barrier than larger AgNPs. Moreover, the comparison 
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of particle size distributions on the maternal and fetal side 
after 6 h of perfusion showed that smaller AgCOONa were 
present on the fetal side (up to 96 nm) in comparison to the 
maternal side (NPs / aggregates up to 230 nm) and the 
particles accumulated in placental tissue (up to 140 nm). 
Assuming the second scenario (translocation of dissolved Ag 
followed by Ag reduction or reaction with available ligands), 
the higher translocation of Ag in case of AgPEG NPs in 
comparison to AgCOONa NPs could be explained with the 
larger mass fraction of dissolved Ag of 4.9 % in comparison to 
0.1% in the NP formulations and/or potentially higher 
solubility of AgPEG NPs.  
HSI analysis indicated that the NPs detected in placental 
tissue were (at least to some extent) the pristine AgNPs, which 
means that complete dissolution of the AgNPs on the maternal 
side can be excluded. The finding does, however, not allow to 
conclude that pristine AgNPs translocated to the fetal side.  
In summary, our study demonstrates that the derivatised 
AgNPs underwent complex reactions in the conducted 
translocation studies due to their readily soluble nature and 
their chemical reactivity. In order to distinguish between 
translocation of intact AgNPs and that of dissolved Ag/ions 
originating from the NPs further studies are needed, where 
other methods for determining chemical composition of 
translocated AgNPs (e.g. energy dispersive x-ray 
spectroscopy
52,57
) are required. Another possibility would be 
isotope labeling in combination with conventional ICP-MS, 
which however can suffer from the risk of artificial and/or 
false-positive results associated with labeled materials (e.g. 
loss of label and changes in NP properties and biointeractions). 
Moreover, distinguishing between particulate and ionic silver 
would require additional separation techniques such as 
filtration or centrifugation. These additional steps could result 
in retention of the ionic Ag-macromolecule fraction to the 
filter or co-precipitation in centrifugation due to a reaction of 
ionic Ag with macromolecules in biological environments. This 
could be problematic in particular for this study where we deal 
with very low amounts of translocated Ag. The use of two 
stable Ag isotopes could be another promising approach to 
monitor the transformation of AgNPs and dissolved Ag in 
biological systems by spICP-MS.
58
 However, using an enriched 
Ag isotope label in conjunction with spICP-MS is not yet 
possible since only one isotope can be detected by most ICP-
MS instruments (some quadrupole ICP-MS instruments are 
able to switch between two masses during high time 
resolution measurements but quantitative mass analysis is 
hardly possible with this technique because important peak 
information is lost during the mass switching time and signal 
intensities will suffer from spectral intensity skew error
59
).  
 
Comparison of translocation data with other studies 
So far, potential AgNP translocation across the placenta has 
only been investigated in pregnant rodents. The translocation 
levels of Ag, measured by ICP-MS in the tissues of pups as the 
total Ag mass concentrations and expressed as the 
percentages of the administered dose, ranged from 0.008–
0.009%,
23
 0.036%,
11
 0.085–0.147%,
22
 0.097%
59
 to 0.2-0.5%,
24
 
while the percentage of Ag accumulated in placental tissue 
varied between 0.2%
13,23
 and 0.04-1.3%.
24
 In our study Ag 
translocation across the human placental barrier (0.015-
0.062%, calculated as Ag mass fraction > and ≤ 25 nm) was in 
the same range as those observed in rodent studies, while the 
percentage of accumulated Ag in the placental tissue was 
about 10-times higher (12-16%). Although significant biological 
differences in placental structure and function between 
humans and rodents may contribute to the observed 
differences, a direct comparison is challenging due to 
additional physico-chemical differences in the NP types (size, 
surface modifications), applied doses and routes of 
administration, among others. For instance, the higher 
observed accumulation of Ag in human placental tissue is most 
probably related to the different doses of AgNPs at the 
placental barrier. In in vivo experiments where AgNPs were 
intravenously or orally dosed to the rodents, NPs were not 
only distributed to the placenta but also to other  maternal 
organs, mainly the liver and kidneys.
52
 Therefore, 
biodistribution studies in rodents will still be highly valuable to 
provide an estimate of the expected doses at the placental 
barrier while human ex vivo placenta perfusion studies can 
deliver important mechanistic insights on NP translocation and 
accumulation at the intact human placental barrier.    
Conclusions 
Different surface properties of the selected AgNPs (neutral and 
negatively charged coatings), which can affect their solubility 
and size through aggregation/agglomeration in PM, most 
probably influence different translocation and accumulation 
behavior of Ag. The results further demonstrate that particles 
detected on the fetal side are not necessarily the result of 
translocated pristine AgNPs, but could also be Ag precipitates 
formed from dissolved Ag that crosses the placental barrier. 
The detected Ag-containing particles in the fetal circulation, 
which can result from translocation of intact AgNPs or from re-
precipitated Ag, were in the same concentration and size 
range, which hampered the identification of any translocation 
mechanism of AgNPs. Therefore, careful assessment of particle 
dissolution and their possible re-precipitation under 
physiological conditions as well as the inclusion of ionic 
controls should be an integral part of future translocation 
studies with soluble NPs. Such measure would enable accurate 
interpretation of the results and help to identify strategies 
towards prevention of placental transfer of nanomaterials. 
Although translocation was low for both NP types the small 
amount of translocated ions/NPs may be sufficient to 
adversely affect fetal health, which should be carefully 
addressed in future studies. 
Our study further demonstrates that spICP-MS is a 
promising technique to study the translocation of NPs. In 
contrast to conventional ICP-MS, which was used in other 
published studies dealing with translocation,
23,24,60
 spICP-MS 
additionally provides information on the NP size distribution. 
This allows studying NP changes like dissolution/aggregation 
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and, in this way, helps identifying mechanisms of transport. 
Theoretically, spICP-MS can even distinguish between NPs and 
the dissolved fraction of the analysed element if the size of the 
studied NPs does not overlap with the minimum detectable 
size.  
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with AgPEG and AgCOONa NPs. 
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